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Background.—Cluster headache (CH) is commonly regarded as one of the most disabling headache conditions, and
referred to as one of the most painful conditions known to humankind. Although there has been some research indicating the
severe impact of CH, there is little comprehensive evidence of its impact on quality of life, disability, mood, and cognitive
function in both its episodic (ECH) and chronic (CCH) variants.
Methods.—This cross-sectional study investigates various aspects of cognitive function including intelligence, executive
function, and memory, and mood, disability, and quality of life in 22 patients with ECH and CCH compared with age-matched
healthy controls.
Results.—The results showed that intelligence and executive functions are intact in patients with CH, but that patients with
CH perform significantly worse than healthy controls on tests of working memory and (all P < .05) report greater cognitive
failures (P < .05). Around one third of both the ECH and CCH groups achieved “caseness” for depression, while self-reported
anxiety was higher in those with CCH than the ECH patients, with 75% of the former compared with 38% of the latter groups
achieving “caseness” on the measure of anxiety. Patients with CH reported high levels of disability, which was not significantly
different between the 2 groups (P > .05). The patients with CH reported poor quality of life compared with healthy controls;
however, this difference was not statistically significant.
Conclusion.—Patients with CH show worse working memory, disturbance of mood, and poorer quality of life compared
with healthy controls. The differences between patients with ECH and CCH, and the implications of these findings for the
management of CH are discussed.
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Cluster headache (CH) is considered to be one of
the most painful conditions known to humankind,
with female patients describing the headache attacks
as being more painful than childbirth.1,2 There are 2
types of CH, episodic (ECH) and chronic (CCH), and
while the pain experienced by both groups is similar,
they are distinguished by the frequency of the
attacks.3 CH usually occurs in cluster periods and is
therefore more commonly ECH, while only around
15-20% of the patients suffer from CCH without
remission.3
Patients suffering from CH experience unilateral
pain and due to the excruciating intensity of the pain,
violent self-harm at the site of the pain and attempted
suicide are often reported.4,5 Inevitably, this painful
condition has a negative influence on the patient’s life
and general well-being.
There has been some research looking at the
impact of CH on quality of life (QoL) and daily func-
tioning.These have shown poorer well-being on many
domains of QoL6,7 and increased disability due to the
impact of the headache.8-10 The level of impairment in
QoL in CH has been reported to be similar to that
documented in migraine,7 while disability due to
headache has been reported to be higher in patients
with CH than those with migraine.8 However, while
migraine is very well researched and there is much
evidence illustrating its impact, the influence of CH
continues to be under-represented. Similarly, there is
limited evidence documenting the psychological well-
being of patients with CH. Researchers have shown
that patients with CH experience high levels of
anxiety disorders9,11 and increased depression, agora-
phobic symptoms, and suicidal tendencies relative to
healthy controls (HCs).8 A recent population-based
follow-up study also showed that patients with CH
are at a greater risk of developing depression com-
pared with HCs.12
In addition to the adverse impact that CH has on
the patient’s life and general well-being, cognitive
dysfunction has also been associated with CH. Since
the structures known to serve memory and executive
function are involved in the development of CH,13-17
there has been some investigation of cognitive func-
tion in CH. While some researchers have shown
impairments in verbal memory functions,11 others
report no significant differences in memory or execu-
tive function between participants with CH and
HCs.18 Similarly, data obtained from neurophysiologi-
cal studies suggest that cognitive processing in CH is
affected only during active headache attacks and
therefore propose that any impairment may be due to
the pain experienced.19-21 According to studies
looking at the impact of pain on cognitive perfor-
mance, chronic and persistent pain stimuli can be
highly demanding of attentional resources which can
then impair cognitive performance.22,23
These studies highlight the marked negative
influence that CH can have on the patients’ lives,
compromising their sense of well-being and their
ability to function normally. However, the majority of
these studies are based on either patients with ECH
or CCH alone, or they lack appropriate comparison
of the data to a normal population to illustrate the
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clinical significance of any differences found.7,10,11,18
Thus in an attempt to provide a clearer account of the
impact that both ECH and CCH can have on the
patients lives, we aim to investigate key components
of cognitive (intelligence, executive function, and
memory) and psychosocial function (mood, disability,
and QoL) compared with a matched HC group.
METHODS
Sample.—The sample consisted of 3 groups: CCH
(N = 11), ECH (N = 11), and HCs (N = 12) (please
see Table 1 for details). The patients with CH were
consecutively recruited from the outpatient clinic of
the tertiary headache referral center at the National
Hospital for Neurology and Neurosurgery (Queen
Square, London). The sample size was derived from
the number of cases attending the tertiary clinic that
met the inclusion criteria. This size was considered
adequate based on previous studies investigating this
subject in this client group.
The patients with CH fulfilled the International
Headache Classification (ICHD-II) criteria for ECH
and CCH.3 According to this classification, CCH con-
sists of 10-15 continuous attacks without remission
that last between 15 and 180 minutes and occur
between 1 and 8 times per day. ECH consists of 2
cluster attacks for at least 7 days that can last for
several weeks or months, and are separated by a
remission period of several months to many years. For
better comparison of performance, ECH patients in
this sample were tested during an active headache
bout. Patients with other co-existent headache disor-
ders and/or history of any psychiatric or neurological
condition, head injury, or those that had received sur-
gical treatment for CH were excluded.
The HCs were the spouses of the patients seen at
the clinic, who also had no history of headache diag-
noses, psychiatric illness, head injury, or any neuro-
logical illness.
Procedure.—This study was approved by the Local
Ethics Committee and conforms to the Declaration
of Helsinki guidelines. All participants gave written
informed consent.
All participants were assessed using validated
instruments for measuring cognitive and psychosocial
functioning for the purposes of this study only.
The data for this study were collected during 2011
and 2012.
Cognitive Assessment.—The participant’s global
cognitive functioning, intelligence, executive func-
tioning, and memory were measured using the follow-
ing assessment tools:
Global Cognitive Functioning and Intelligence.—
Mini-Mental State Examination (MMSE)24 is a
30-item measure of global cognitive functioning cov-
ering: orientation, memory, language, and executive
function. The score range is 0-30, with higher scores
representing better cognitive functioning. Scores
Table 1.—Demographic and Clinical Details of Patients with Episodic (ECH) or Chronic Cluster Headache (CCH) and Healthy
Controls (HCs)
HC ECH CCH
(n = 12) (n = 11) (n = 11) P
Age (years) 53.17 ± 16.25 40.82 ± 15.11 49.18 ± 11.02 .552
Gender
Male 33% 73% 82% .038
Female 67% 27% 18%
Education (years) 14.50 ± 2.15 15.27 ± 2.76 14.36 ± 4.20 .642
Age at onset (years) 30.00 ± 17.60 34.55 ± 10.85 .341
Disease duration (years) 10.82 ± 15.15 14.64 ± 11.48 .232
CH side
Left (%) 18% 45.5% .264
Right (%) 73% 45.5%
Bilateral (%) 9% 0%
Unilateral (%) 0% 9%
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below 24 are considered to indicate cognitive
impairment.
The National Adult Reading Test (NART)25 is a
test of premorbid intelligence quotient (IQ) that
requires participants to read out loud a set of 50
English words that are presented in order of increas-
ing difficulty. The test taps vocabulary and reading
ability, 2 areas of cognitive function least affected by
cognitive decline, and thus commonly used to esti-
mate premorbid IQ. The words presented have
irregular grapheme and phoneme correspondence,
and thus accurate reading would require previous
knowledge of the word. The total error score is used
to estimate premorbid IQ.
The Wechsler Abbreviated Scale of Intelligence
(WASI)26 is a measure of current IQ, consisting of 4
subscales: vocabulary, similarities, block design, and
matrix reasoning. In the abbreviated version, the
vocabulary and matrix reasoning subtests are used to
calculate the full-scale IQ. The vocabulary subtest
measures the individual’s verbal knowledge and
verbal concept formation. The matrix reasoning
subtest provides information about the patient’s non-
verbal fluid reasoning such as visual information pro-
cessing and abstract reasoning skills.
Executive Functioning.—The Delis–Kaplan
Executive Function System (D-KEFS)27 is a neuro-
psychological test of verbal and nonverbal executive
functions. It consists of various subtests. In this study,
the following subtests were used to assess executive
function:
The Trail Making Test (TMT) is a test of behav-
ioral regulation that consists of 5 subtests: (1) visual
scanning: the participants crosses out all “3” among
both letters and other numbers; (2) number sequenc-
ing: the participant connects all numbers in successive
order, ignoring any letters on the sheet; (3) letter
sequencing: the participant connects letters in alpha-
betical order, ignoring any numbers on the sheet; (4)
number-letter switching: the participant connects
circles switching between the ones containing digits
and letters (1-A-2-B-. . .) in 2 alternating sequences;
and (5) motor speed: measures general motor speed
and requires the subject to trace dashed lines con-
necting empty circles as fast as possible. In addition to
scaled scores for each subtest, a contrast score of
“letter-number switching-letter sequencing” score
can be computed, directly quantifying relative perfor-
mance on a baseline task and a higher-level task
requiring switching and set shifting.
Verbal fluency (VF) is made up of 3 tasks each
performed as fast as possible for 60 seconds: (1) letter
fluency: the participant generates words beginning
with a particular letter: F, A, S; (2) category fluency:
the participant generates words belonging to a desig-
nated category: animals, boys’ names; and (3) cat-
egory switching: the participant alternates between
generating words from 2 semantic categories, fruit
and furniture. For each subtest, the total number of
correct words generated is recorded and scaled scores
are calculated.
The Color-Word Interference Test (Stroop)
assesses the ability to inhibit proponent responses
and contains 4 subtests: (1) color naming: naming
colored rectangles; (2) word reading: reading the
color words red, green, and blue printed in black ink;
(3) inhibition: naming the color of ink of color words
written in an incongruent ink color (eg, word red
printed in green ink); and (4) inhibition/switching:
naming the color of ink of color words printed in an
incongruent ink and switching to reading the word
when the stimulus is presented in a box.Total comple-
tion time and self-corrected and uncorrected errors
are noted. Scaled scores are obtained for each subtest.
An inhibition–color naming contrast score is also
computed.
Verbal and Non-Verbal Memory.—California
Verbal Learning Test (CVLT)28 is a measure of verbal
short-term and long-term memory. It assesses recall
and learning across 5 repetitions and recognition of a
list of 16 words belonging to 4 semantic categories
presented at immediate and delayed recall trials.
Immediate presentation and recall of a second list to
test proactive interference is followed by testing of
free and cued recall of the first trial. Delayed recall is
also tested after a 20-minute delay, followed by
delayed free and forced choice recognition trials.
The Warrington Short Recognition Memory for
Faces (SRMF)29 is a test of recognition memory for
unfamiliar faces.A short version of this test was used,
which consists of the presentation of 25 faces at a rate
of 1 picture every 3 seconds, and the participant is
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required to evaluate the presented face as “pleasant”
or“unpleasant.”Subsequently the participants are pre-
sented with 25 pairs of faces and are asked to identify
the previously presented face from each pair.The total
number of faces correctly recognized is recorded.
Working Memory Index (WMI) from the
Wechsler Adult Intelligence Scale (WAIS-III)30 is an
index of working memory function derived from 3 of
the WAIS-III subtests: arithmetic, digit span, and
letter-number sequencing. The arithmetic subtest
involves the verbal presentation of 16 mental arith-
metic problems. The digit span subtest consists of 2
subparts: forward and backward digit span and
assesses immediate auditory span, freedom from dis-
traction, and executive function. The letter-number
sequencing subtest involves ordering numbers and
letters presented in an unordered sequence. Scaled
scores for each subtest as well as aWMI are obtained.
Cognitive Failures Questionnaire (CFQ)31 is a
measure of self-reported deficits in the completion of
simple everyday tasks which a person should nor-
mally be able to complete without error (eg, Do you
fail to notice signposts on the road?). The question-
naire contains items on failures in attention, memory,
perception, and motor function. Each incident is
rated on a 4-point scale indicating its frequency.Total
scores range from 0 to 100 and higher scores indicate
a higher incidence of cognitive failures.
Psychosocial Assessment.—The participant’s mood,
headache induced disability, and health-related QoL
were measured using the following assessment tools:
Mood, Disability, QoL.—The Beck Depression
Inventory (BDI-II)32 is a self-report measure assess-
ing the severity of depression in terms of the
cognitive/affective, somatic, or behavioral symptoms
of depression. Each item is rated between 0 and 3.
Scores on all individual items are added to give the
total BDI-II score. The scores 0-9, 10-18, 19-29, and
30-63 indicate no, mild, moderate, or severe depres-
sion, respectively.
The Hospital Anxiety and Depression Rating
Scale (HADS)33 is a self-report scale to detect depres-
sion and anxiety. It is composed of a 7-item subscale
for depression and a 7-item subscale for anxiety. The
individual items for each subscale are added to give a
total score indicating overall anxiety (HADS-A) and
depression (HADS-D).The total score range for both
subtests is 0-24, with scores above 8 and 11 indicating
“possible” and “definite” “caseness” for anxiety/
depression, respectively.
The Beck Hopelessness Scale (BHS)34 is a self-
report inventory measuring 3 major aspects of hope-
lessness: feelings about the future, loss of motivation,
and expectations.The items consist of statements with
which the respondent agrees or disagrees. Scores of
0-3, 4-8, 9-14, and 15-20 indicate minimal, mild, mod-
erate, and severe hopelessness, respectively.
The Migraine Disability Assessment Scale
(MIDAS)35 is a questionnaire assessing disability due
to headache.The MIDAS quantifies the impact of the
headache on a patient’s personal life and occupation.
The total score indicates the level of disability, falling
within 1 of the 4 MIDAS grades: I, II, III, and IV,
indicating little/no (total: 5 or less), mild (total: 6-10),
moderate (total: 11-20), and severe (total: 21 or more)
disability respectively.
The Headache Impact Test (HIT-6)36 is a ques-
tionnaire assessing the impact of the headache on a
patient’s ability to function in his/her daily life. Each
item has a frequency response and is assigned an item
category weight (6, 8, 10, 11, and 13).All item category
weights are summed to form the total score indicating
little/no impact (total: 49 or less), some impact (total:
50-55), substantial impact (total: 56-59), or very
severe impact (total: 60 or more).
EuroQoL (EQ5D)37 is a questionnaire covering 5
dimensions of QoL: mobility, self-care, usual activi-
ties, pain/discomfort, and anxiety/depression. The
subscores can be combined to give a summary index
value of 0-1. The EQ5D also includes a visual analog
scale or thermometer for rating “current health
state.” Lower scores represent poorer QoL for both
parts of the test.
The Scales for Outcomes in Parkinson’s disease –
Autonomic (SCOPA-AUT)38 is a questionnaire
assessing autonomic symptoms in 6 categories: gastro-
intestinal, urinary, cardiovascular, thermoregulatory,
pupillomotor, and sexual dysfunction.Each itemmea-
sures the presence of a specific autonomic problem,
and is rated between 0 and 3 on its frequency.The scale
gives a total score ranging from 0 to 78 with higher
scores indicating more autonomic symptoms.
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Statistical Analyses.—The analyses were con-
ducted using IBM SPSS (Statistical Package for the
Social Sciences, Armonk, NY, USA). Chi-square test
of association was used to report frequencies of data
for descriptive purposes, and the inferential analyses
included a series of multivariate analyses of variance
(MANOVAs). The independent variable was group
(HC vs ECH vs CCH) and the dependent variables
were the cognitive and psychosocial assessment mea-
sures. Where necessary, Tukey test was used for post
hoc analysis. Pearson product-moment correlation
coefficient was used for subsequent correlation analy-
ses.
RESULTS
There were no statistically significant differences
in key demographic variables between the 3 groups
(P > .05), except for gender (see Table 1). The head-
ache groups did not differ in terms of key clinical
variables including age of onset, disease duration, or
side of CH (P > .05) (see Table 1).
Cognitive Function.—Three MANOVAs were per-
formed to compare the 3 groups in terms of intelli-
gence, executive functioning, and memory. The mean
and standard deviations for each group and the
results of the analyses are presented in Table 2.
Measures of Intelligence.—Both the current IQ
and estimates of premorbid IQ for the 2 headache
groups were in the “average range,” with no discrep-
ancy between the 2 measures. For the HCs, current IQ
was in the superior range and estimated premorbid IQ
was in the high average range. There were no statisti-
cally significant differences between the 3 groups in
measures of current IQ (WASI-FSIQ: F[2,29] = 3.130,
P = .059), estimated premorbid IQ (NART-FSIQ:
F[2,29] = 0.968, P = .392), or global cognitive func-
tioning (MMSE: F[2,29] = 1.660, P = .208) (see
Table 2).
Measures of Executive Functioning.—Executive
functioning was measured using subtests of the TMT,
VF, and Stroop. The MANOVA results yielded no
statistically significant differences between the 3
groups on any of the measures (see Table 2), except
on the letter sequencing and number-letter switching
subtests of the TMT (F[2,27] = 4.492, P = .021 and
F[2,27] = 3.416, P = .048 respectively). Following a
Bonferroni correction, setting alpha at 0.001, these
statistical significances remained.
Post hoc comparisons using Tukey showed that
these significant results were due to the difference in
the means of the HCs and ECH patients with the
latter group performing worse (P < .05 on both tests)
(see Fig. 1).
Interestingly, the ECH patients performed
poorer on most subtests of TMT than CCH patients,
although the differences did not reach significance
(see Table 2).
Measures of Memory Function.—Memory func-
tion was assessed using the CVLT-II for verbal epi-
sodic memory, WAIS-III subtests for working
memory, Warrington SRMF for non-verbal episodic
memory, and CFQ for subjective memory.There were
no statistically significant differences between the 3
groups on the CVLT-II and the arithmetic subtest of
the WAIS-III WMI (see Table 2). There were group
differences on the other 2 subtests of WAIS-III, the
Warrington SRMF, and the CFQ (see Table 2 and
Fig. 2). These statistical differences remained follow-
ing a Bonferroni correction to account for the mul-
tiple comparisons.
Post hoc analyses of the WAIS-III subtests using
Tukey’s test showed a statistically significant differ-
ence in the mean scores for HCs and both ECH and








Fig 1.—Means and standard errors for patients with episodic
and chronic cluster headache and healthy controls on 2
subtests of the Trail Making Test. HCs = healthy controls;
ECH = episodic cluster headache; CCH = chronic cluster
headache.
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number sequencing, only the CCH group scored
significantly lower than HCs (P < .05), and the differ-
ence between HCs and the ECH group was not
(P = .07).On theWMI subtest, the ECH group scored
significantly lower than the HCs (P < .05), and the
difference between HC and CCH groups just missed
significance (P = .06). For both of these subtests, the
headache groups did not differ from each other
(P > .05) (see Fig. 2a).
On theWarrington SRMF, post-hoc tests showed
that the differences between the 3 groups were not
statistically significant (P < .05). The 3 means were
homogenous (see Fig. 2b). On the CFQ, the HC
means were significantly lower (less cognitive fail-
Table 2.—Means and Standard Deviations for the Measures of Intelligence, Executive Function and Memory Function
HCs ECH CCH P
Measures of intelligence
WASI –full-scale IQ 124 ± 7.44 112.11 ± 15.42 114.27 ± 12.56 .059
NART –full-scale IQ 118.33 ± 6.47 112.91 ± 7.70 114.55 ± 9.18 .392
Mini Mental State Examination 29.00 ± 1.13 28.18 ± 1.66 29.36 ± 1.03 .208
Measures of executive function (D-KEFS)
TMT scaled scores
Visual scanning 11.45 ± 2.07 10.70 ± 2.50 9.09 ± 3.08 .169
Number sequencing 11.91 ± 2.17 11.30 ± 1.77 11.91 ± 1.45 .524
Letter sequencing 12.64 ± 1.86 10.10 ± 3.04 11.00 ± 1.27 .021*
Number-letter switching 12.73 ± 1.49 9.10 ± 3.90 10.18 ± 3.00 .048*
Motor speed 11.64 ± 1.29 10.10 ± 3.51 10.55 ± 1.57 .238
Letter-number switching vs letter sequencing 10.09 ± 1.14 8.56 ± 3.245 9.36 ± 2.157 .312
Verbal fluency scaled scores
Letter 13.33 ± 3.73 11.56 ± 4.50 8.82 ± 3.82 .077
Category 12.25 ± 3.42 11.22 ± 4.21 10.73 ± 4.20 .856
Category switching 11.83 ± 3.49 11.78 ± 4.60 10.27 ± 2.72 .625
Color-word interference test scaled scores
Color naming 10.10 ± 2.89 8.70 ± 1.95 8.36 ± 2.84 .315
Word reading 11.55 ± 2.34 9.10 ± 3.35 10.00 ± 2.15 .265
Inhibition 13.27 ± 2.24 10.80 ± 2.39 10.27 ± 3.55 .070
Inhibition/switching 12.45 ± 2.58 10.60 ± 2.50 11.45 ± 2.12 .493
Inhibition vs color naming 13.18 ± 1.94 12.11 ± 2.26 11.73 ± 2.69 .303
Measures of memory function
CVLT-II raw scores
Trial 1 6.46 ± 1.81 6.20 ± 2.25 6.64 ± 2.54 .704
Trial 1-5 55.09 ± 11.14 50.00 ± 10.93 49.18 ± 18.36 .620
Short delay-free recall 12.09 ± 2.63 10.11 ± 2.47 9.00 ± 5.35 .224
Short delay-cued recall 12.90 ± 2.73 11.33 ± 2.50 9.91 ± 5.45 .246
Long delay-free recall 12.64 ± 2.50 11.30 ± 2.71 9.36 ± 6.31 .216
Long delay-cued recall 12.73 ± 2.10 11.40 ± 2.80 10.09 ± 5.00 .228
Recognition-hits 15.18 ± 1.25 14.10 ± 2.18 13.55 ± 2.84 .192
Recognition-false positives 1.27 ± 1.27 1.80 ± 1.87 2.91 ± 3.20 .434
WAIS-III Working Memory Index (WMI) subtests scaled scores
Arithmetic 12.50 ± 2.51 9.56 ± 3.58 10.10 ± 2.17 .129
Digit span 13.58 ± 2.81 8.90 ± 3.10 9.00 ± 3.50 .011*
Letter-number sequencing 13.92 ± 2.61 10.50 ± 3.70 10.30 ± 2.54 .025*
Working Memory Index 120.00 ± 13.78 98.63 ± 20.52 98.60 ± 13.96 .019*
Warrington Short Recognition Memory for Faces
Correct responses (max25) 23.00 ± 2.00 20.82 ± 3.40 20.73 ± 3.66 .050*
Cognitive Failures Questionnaire
Cognitive Failures Questionnaire 31.83 ± 10.11 41.38 ± 21.51 41.50 ± 18.27 .009*
CCH = chronic cluster headache;ECH = episodic cluster headache;HCs = healthy controls;NART = NationalAdult ReadingTest;
WASI = Wechsler Abbreviated Scale of Intelligence; *P < .05.
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ures) than CCH (P < .05) but not the ECH patients
(P > .05) (see Fig. 2c). The CCH group exhibited
higher scores showing more cognitive failures, fol-
lowed by ECH patients and then HCs (see Table 2).
Psychosocial Function.—Two separate MANOVAs
were conducted on measures of mood, disability, and
QoL. The first one examined differences in mood
between the 3 groups, and the second analysis evalu-
ated differences in disease impact and QoL. The
descriptive results and their significant values are pro-
vided in Table 3.
Measures of Mood, Disability, and QoL.—The
first analysis showed significant group differences on all
measures of mood and autonomic dysfunction: BDI-II
(F[2,25] = 18.482, P = .000), HADS-A (F[2,25] = 5.497,
P = .011), HADS-D (F[2,25] = 19.140, P = .000), BHS
(F[2,25] = 9.358,P = .000), and SCOPA-AUT (F[2,25] =
9.931,P = .000).These statistically significant differences
revealed the same pattern: patients with CCH had the
highest scores on all of the measures, followed by ECH,
and then the HCs (see Fig. 3a). When alpha was
adjusted (P = .001), these statistically significant differ-
ences remained.
A post hocTukey test showed that means for HCs
and the ECH group, and HCs and CCH patients were
significantly different on BHS, BDI-II, and HADS-D,
with the patients scoring worse on all measures (all
P < .005). Post hoc comparisons of means on
HADS-A showed a statistically significant difference
only between HCs and patients with CCH (P < .05),
but not the ECH group (P > .05). Similarly, post
hoc analysis of means on SCOPA-AUT showed
statistically significant differences between the CCH
and HCs groups, and CCH and ECH groups (all
P < .05).
None of the HCs scored in the moderate or
severe depression range on the BDI-II. In contrast,
35% of the ECH and 44% of the CCH groups scored
in the moderately depressed range, and 25% of the
ECH group and 22% of the CCH patients scored in
the severe depression range. This difference between
the 3 groups was statistically significant, indicating
that a significantly higher proportion of the patients
with ECH or CCH experienced moderate or severe
depression compared with the HCs (χ2[2,29] =






















Fig 2.—Mean and standard error for patients with episodic and
chronic cluster headache and healthy controls on tests assess-
ing memory. (a) WAIS-III Working Memory Index subtests;
(b) Warrington Short Recognition Memory for Faces;
(c) Cognitive Failures Questionnaire. HCs = healthy controls;
ECH = episodic cluster headache; CCH = chronic cluster
headache; WAIS-III = Wechsler Adult Intelligence Scale III;
WMI = Working Memory Index.
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Similarly, on the HADS-D,while none of the HCs
achieved “caseness” indicating definite depression,
38% of the patients with ECH and 38% of the CCH
patients did so. The association between group (HC,
ECH, CCH) and “caseness” (yes vs no) for depres-
sion on the HADS-D approached significance
(χ2[2,27] = 5.304, P = .071). However, a significantly
higher proportion of the patients with ECH or CCH
achieved “caseness” for anxiety on HADS-A than the
HCs. (χ2[2,28] = 9.307, P < .05). One participant in
the HCs group (8%), 38% of the ECH group, and
75% of the CCH patients achieved “caseness” for
anxiety as measured on HADS-A.
The second analysis revealed no differences in
QoL between the 3 groups (EQ5D health state:
F[1,13] = 1.049, P = .325; EQ5D thermometer:
F[1,13] = 0.963, P = .344). Similarly, there were no
group differences between the headache groups con-
cerning the impact of their headache (HIT-6:
F[1,13] = 0.026,P = .875) or headache-related disabil-
ity (MIDAS: F[1,13] = 2.674, P = .126).We then com-
bined the 2 headache groups, to compare QoL
betweenHCs andCHpatients.The results revealed no
difference in the EQ5D health state (F[1,28] = 0.054,
P = .818) but showed a statistically significant group
difference in the EQ5D visual analog scale rating of
overall health status (F[1,28]: 31.104, P = .001), which
a)  BHIS, BDI-II, HADS-D, HADS-A


















Fig 3.—Means and standard errors for (a) hopelessness
(BHS), depression (BDI-II and HADS-D) and anxiety
(HADS-A) and (b) quality of life for the patients with
chronic or episodic cluster headache and healthy
controls. BHS = Beck Hopelessness Scale; BDI-II = Beck
Depression Inventory II; HADS-A = Hospital Anxiety and
Depression Scale-Anxiety; HADS-D = Hospital Anxiety
and Depression Scale-Depression; EQ5D = EuroQoL
quality of life measure; ECH = episodic cluster headache;
CCH = chronic cluster headache; CH = cluster headache;
HCs = healthy controls.
Table 3.—Means and Standard Deviations for the Measures of Mood, Disability, and Quality of Life
HC ECH CCH P
BDI-II 4.92 ± 2.811 19.25 ± 10.74 22.78 ± 6.76 .0001*
HADS-A 5.25 ± 2.864 7.75 ± 6.07 11.63 ± 3.70 .011*
HADS-D 2.08 ± 1.240 8.13 ± 4.02 9.75 ± 3.54 .0001*
BHS 2.58 ± 3.260 10.38 ± 6.12 11.67 ± 5.70 .001*
SCOPA-AUT 6.42 ± 4.209 10 ± 3.703 18.88 ± 9.72 .001*
MIDAS 71.40 ± 59.54 53.13 ± 37.10 .126
HIT-6 64.60 ± 11.86 64.60 ± 4.81 .875
EQ5D- health status 0.89 ± 0.12 1.85 ± 3.82 0.31 ± 0.32 .325
EQ5D- thermometer 85.75 ± 9.29 44.90 ± 23.84 56.00 ± 13.79 .344
A = anxiety; BDI-II = Beck Depression Inventory II; BHS = Beck Hopelessness Scale; CCH = chronic cluster headache;
D = depression; ECH = episodic cluster headache; EQ5D = EuroQoL quality of life scale; HADS = Hospital Anxiety and Depres-
sion rating scale; HCs = healthy controls; HIT-6 = Headache Impact Test-6; MIDAS = Migraine Disability Assessment Scale;
SCOPA-AUT; Scales for Outcomes in Parkinson’s disease – Autonomic; *P < .05.
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as expected was higher in HCs (85.75 ± 9.29) than CH
patients (51.39 ± 19.86) (see Fig. 3b).
Correlational Analysis.—A number of correla-
tional analyses were carried out using Pearson corre-
lation coefficient, to examine the relationship
between demographic and clinical variables (age, age
of onset, disease duration, years of education, side of
CH) and participant’s mood, disease impact, QoL (as
listed in Table 3) and cognitive test results listed in
Table 2. There was a statistically significant negative
correlation between age and MIDAS (r = −0.806,
P < .005), and age and BHS (r = −0.424, P < .05).
Disease duration correlated negatively and statisti-
cally significantly with WASI FSIQ (r = −0.459,
P < .05) and also with 2 measures of the CVLT-II
(negatively with the long delay free recall: r = −0.463,
P < .05; and positively with false positives on the rec-
ognition test: r = 0.527, P < .05). Furthermore, there
was a negative correlation between age at onset and
MIDAS (r = −0.466, P < .05), and years of education
and the category subtest of VF (r = −0.414, P < .05).
None of the other correlations were statistically sig-
nificant or noteworthy. It was not possible to statisti-
cally adjust the alpha to account for multiple
comparisons due to the sample size.Thus these should
be interpreted with caution.
DISCUSSION
There is some evidence available that illustrate
the negative impact of CH. However, to our knowl-
edge, there are no data available that compare
patients with ECH and those with CCH with HCs on
measures of QoL, daily functioning, mood, and cog-
nition, which was the aim of this study.
Cognitive Function in CH.—We assessed intelli-
gence, executive function, and memory. The results
showed comparable scores on a global measure of
cognitive ability, and premorbid and current IQ for
CHpatients,andage-matchedHCs,andno statistically
significant differences were found on most measures
of executive function.However, patients with CH per-
formed worse on some of the working memory and
TMT subtests and reported more cognitive failures.
In terms of intelligence, the patients in our
sample did not differ significantly from HCs on mea-
sures of IQ or global cognitive functioning. The
premorbid and current IQ in the patient groups was
in the average range, and although the IQ of HCs was
in the superior/high average ranges, they did not
differ statistically significantly from patients with CH.
The only deficit in executive function shown by
patients with CH relative to HCs was for the letter
sequencing and number-letter switching subtests of
TMT. However, conversion of the scores into scaled
scores based on the population means for their
respective age groups did not show a great variation.
They indicated that the 3 groups (HC, ECH, CCH)
had scaled scores of 12, 10, and 11 on the letter
sequencing and 12, 9, and 10 on the number-letter
switching subtest. Furthermore, interestingly, patients
with ECH performed worse than those with CCH on
most subtests, but the differences were small and
therefore not statistically significant. These differ-
ences could be indicative of reduced mental flexibility
in patients with CH, particularly those with ECH. A
trend was also observed for the letter fluency subtest
of the D-KEFS, with CCH patients performing worse
than the 2 other groups. Future results from a larger
sample would clarify if this difference can reach sig-
nificance. The mean scaled scores of all groups fell
within the average to high average performance
range on the measures of executive function, and
were mostly not statistically significantly different
from HCs. In addition, since the tests administered
tapped various aspects of executive function, this
aspect of cognitive function can be considered intact
in both ECH and CCH.
Overall, these results confirm previous research
in showing no major deficits in the executive function
of patients with ECH11 and CCH,18 and extend this
yet further by comparing the performance of both
groups on the same measures. This study also pro-
vides unique data on measures of memory, particu-
larly the working memory in patients with ECH and
CCH.Our results revealed that CCH patients showed
greater impairment on tests that required informa-
tion to be re-ordered (letter-number sequencing), ie,
necessitating manipulation of information held in
working memory, while the ECH patients performed
statistically significantly worse on the WMI of the
WAIS-III, which provides a general measure of
working memory.
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TheWMI for the HCs was 120, compared with 98
for the 2 CH groups. In terms of clinical significance,
the mean scaled scores indicated average perfor-
mance for all working memory subtests in the 2 head-
ache groups, while performance in the HC group was
found to be within a high average range. Therefore,
the observed statistical difference in working memory
function between the 2 patient groups and the HC
group is not suggestive of significant clinical deficits
since their performance remained in the average
range despite being significantly lower than HCs sta-
tistically. In addition, the results of the 3 groups,
including the headache groups, do not vary greatly
from the population mean and standard deviation of
the scaled scores of the individual subtests (10 and 3,
respectively) or the WMI (100 and 15, respectively).
However, when patients were asked to rate the
severity of their own cognitive failures, patients with
CCH reported higher cognitive failures than the
ECH patients, and statistically significantly higher
failures than HCs.Although this may be a true reflec-
tion of greater deficits in patients with CCH which
would be consistent with their poorer performance
on working memory tests, an alternative explanation
would be that CCH patients are less confident about
their mnemonic abilities compared with ECH
patients, especially when we consider the higher
levels of anxiety in patients with CCH. Furthermore,
contrary to previous reports of reduced verbal
memory function in CH,11 our results did not show
any statistically significant differences between either
of the headache groups and HC onmeasures of short-
and long-term episodic verbal memory.
This study provides a comprehensive account of
cognitive function in patients with CH, both ECH and
CCH. The results indicate that intelligence, executive
function, and episodic memory are largely intact in
patients with CH, and where deficits are observed, they
are of little clinical relevance and do not impair the
normal cognitive functioning of the patients. Further-
more, although there has been evidence suggesting a
pivotal role of the hypothalamus in the development of
CH,21,39-42 given the pure neuropsychological nature of
this study, however, no statement can be made on the
neural basis of the observed deficits.This remains to be
investigated in future studies.
Psychosocial Function in CH.—We investigated
the impact of CH on various measures of mood and
autonomic symptoms, disability, and QoL.
In line with previous studies, our results showed
that patients with CH (both ECH and CCH) had
increased rates of depression, anxiety, hopelessness,
and autonomic symptoms relative to HCs.8,9,12,13 Inter-
estingly, although the number of patients achieving
“caseness” for depression was identical in both head-
ache groups (38%), a larger proportion of the CCH
patients (75%) achieved “caseness” for anxiety than
the ECH group (38%). Since CCH patients do not
experience a period of remission, the higher incidence
of anxiety in this group is perhaps a reflection of the
implications of having a chronic disorder. The
SCOPA-AUT, which is a measure mainly used for
assessing autonomic symptoms of patients with Par-
kinson’s disease was used to identify the presence of
any autonomic symptoms in this sample and to iden-
tify if the headache frequency affected the severity of
these. Interestingly, the findings did show that patients
with CCH experienced significantly more autonomic
symptoms not only than HCs but also than ECH suf-
ferers, while patients with ECHs did not show a sta-
tistically significant difference from HCs. The
unpredictable and ongoing nature of the headache
attacks experienced in CCH can have a great impact
on simple activities of daily living and the anxiety
caused can potentially create a sense of “fear” affect-
ing planning of events, socializing, productivity, and
integration in activities.
We also investigated the level of disability
caused by CH by examining the patients’ ability to
function in daily activities (HIT-6) and on personal
and occupational roles (MIDAS), and found no sta-
tistically significant differences between patients
with CCH and those with ECH. Conversely, in a
recent study, Jürgens and colleagues8 examined dis-
ability caused by headache in 130 participants using
the Hospital Headache Disability Inventory. They
compared disability in patients with CCH, ECH in a
bout and ECH in remission, and patients’ with
migraine. Their results showed that the impact of
headache was greatest for CCH patients, followed
by ECH in a bout, ECH in remission, and then those
with migraine.
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Since the participants in our sample were
recruited at the tertiary headache clinic, they would
be expected to display severe cases of headache and
thus the lack of difference between the 2 headache
groups concerning disability is not surprising.
Although the participants with ECH in our sample
were assessed during an active headache attack and
their scores may only be applicable to disability as
perceived at the time, the findings illustrate that dis-
ability caused by CH may be similar in both episodic
and chronic types at the time of the attack.The mean
results on the HIT-6 were comparable between the 2
headache groups, and although the mean MIDAS
scores show that ECH patients reported greater dis-
ability than CCH patients, the difference was not
significant.
The correlational analysis showed that younger
patients and those diagnosed at an earlier age
reported higher disease impact on personal and occu-
pational roles. This highlights the importance of con-
sidering interpersonal and demographic details and
how they influence the patients’ ability to cope with
their illness.
Interestingly, contrary to previous literature,6,7
despite severe disability reported by both headache
groups, there were no differences in QoL and health
status (EQ5D) of the 2 headache groups relative to
HCs.However,when theECHandCCHpatientswere
combined to form 1 group, compared with HCs, they
showed significantly lower current health status. Since
the HCs were made up of the partners of our patients,
it is possible that having a spouse with a neurological
condition may have affected their QoL and thus
explains the similarity in their reported QoL when
compared with ECH and CCH patients separately.
CONCLUSION
This study provides neuropsychological data on
the cognitive profile and information about mood,
disability, and QoL, and patients with episodic and
chronic forms of CH from 1 specialist clinic.
A major limitation of this study is that of sample
size, particularly given that a number of multiple
analyses were conducted.Although it is important to
note that multiple testing increases the potential risk
of committing a type I error, in this case of finding a
difference in the measures between the groups when
no such difference exists, the statistically significant
results found here were usually highly significant.
Given that multiple comparisons were made to test
the hypotheses, a Bonferroni correction was applied
to lower the risks of type I error. Following applica-
tion of such a correction, all of the statistically signifi-
cant results remained unchanged. Inevitably with a
larger sample size, it is possible that further significant
results may have been discovered; however, given the
rarity of CH, especially CH in the absence of any
other neurological or psychological diagnosis, the
current sample size is considered adequate. Patients
normally seen at tertiary settings usually have very
severe health conditions, and a great number of
patients seen at this headache clinic had multiple
headache diagnoses. Therefore, for the purposes of
this study, only patients with pure ECH or CCH were
included. Moreover, the majority of previous studies
investigating psychosocial factors and particularly
those investigating cognitive function in CH have had
relatively small samples.7-12,20,21 Nevertheless, further
studies with larger samples are encouraged. Inclusion
of larger samples and controlling for medication
effects on cognition could determine if the observed
effects are actually due to CH rather than possibly
side effects of medication.
Nonetheless, the results presented here highlight
the severe impact of CH on the mental health of both
patients with ECH and CCH compared with HCs. It
particularly highlights the high incidence of anxiety
disorders in this painful and unpredictable condition.
The results also indicate poor QoL and the severely
disabling nature of CH. Despite the impairment in
QoL and high levels of health-related disability and
psychiatric comorbidity found in CH, cognitive func-
tion remained largely intact in both ECH and CCH
patients included in this sample, thus confirming pre-
vious reports of intact cognition in CH patients.
The high levels of disability and mood distur-
bance in CH warrants direct management of these
problems in clinical practice.Anti-depressant medica-
tion and/or psychotherapy to help patients come to
terms with the disabling nature of their CHsmay both
prove of value. Despite some differences between
CCH and ECH found in this study, the results indi-
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cate that CH can have a severely disabling and
negative influence on various aspects of living and
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